Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

155.18 +0.20 (+0.13%)
Streaming Delayed Price Updated: 2:33 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
News headline image
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment ↗
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,  
Via Benzinga
News headline image
7 Tech Stocks to Watch on July 14 ↗
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? ↗
Read the latest report on NanoViricides here. 
Via Benzinga
News headline image
Is Johnson & Johnson Stock a Buy Now? ↗
Some businesses never go out of style. 
Via The Motley Fool
News headline image
This Is What Whales Are Betting On Gilead Sciences ↗
 
Via Benzinga
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Gilead Sciences' Debt Overview ↗
 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy In July ↗
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
News headline image
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment ↗
Read the latest report on NanoViricides here. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Amgen Inc. Dividend Stock Analysis ↗
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
News headline image
Ominous Death Cross Forms On Gilead Sciences's Chart ↗
 
Via Benzinga
News headline image
Expert Ratings for Gilead Sciences ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
2 Low-Priced Stocks That Could Make You Richer ↗
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
News headline image
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows 
Via News Direct
News headline image
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years ↗
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for  
Via Benzinga
News headline image
Alleged Industrial Espionage Makes an Interesting Story ↗
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
News headline image
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
News headline image
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls ↗
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
News headline image
How to Retire Rich: Biotech Stocks Edition ↗
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
News headline image
5 Stocks to Buy With Explosive 500% Potential ↗
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy in June ↗
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
3 Dividend Stocks You Can Buy Without Any Hesitation ↗
The choices are easy with these stocks. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.